V. Bramwell

4.6k citations

67 papers · 3.5k indexed · h-index 27

Internal Medicine top 1%
Oncology top 1%
- Vascular Tumors and Angiosarcomas 23
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 4
Cancer Research top 2%
- Breast Cancer Treatment Studies 14
Pulmonary and Respiratory Medicine top 1%
- Sarcoma Diagnosis and Treatment 32
- Advanced Breast Cancer Therapies 4
Rheumatology top 2%
Molecular Biology
- Cancer therapeutics and mechanisms 6
Genetics
- Estrogen and related hormone effects 5

Co-authors: Mark N. Levine Kathleen I. Pritchard Armando Santoro J. Buesa David Warr Lois E. Shepherd Michael Gent Andrew Arnold
Cited by: Internal Medicine Oncology Cancer Research
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (9 papers)European Journal of Cancer (6 papers)
Partner nations: Canada United Kingdom Netherlands

In The Last Decade

V. Bramwell

67 papers receiving 3.3k citations

Peers

Countries citing papers authored by V. Bramwell

Since Specialization

Citations

This map shows the geographic impact of V. Bramwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Bramwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Bramwell more than expected).

Fields of papers citing papers by V. Bramwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Bramwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Bramwell. The network helps show where V. Bramwell may publish in the future.

Co-authorship network

The 25 scholars most cited alongside V. Bramwell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with V. Bramwell Line = papers co-authored together V. Bramwell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Annals of Oncology ·Rinat Yerushalmi,Bin Dong,Judith‐Anne W. Chapman,Paul E. Goss,Michaël Pollak,Margot J. Burnell,Mark N. Levine,V. Bramwell,Kathleen I. Pritchard,Timothy J. Whelan,James N. Ingle,Lois E. Shepherd,Wendy R. Parulekar,Lei Han,Keyue Ding,Karen A. Gelmon	2017	21
2	Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC) Annals of Oncology ·Yi Yan,Saba Naeem,Anne Blanchard,V. Bramwell,Kathleen I. Pritchard,Dongsheng Tu,Lois E. Shepherd,Yvonne Myal,Carla Penner,Peter H. Watson,Etienne Leygue,Leigh C. Murphy	2013	45
3	Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy JNCI Journal of the National Cancer Institute ·F P O’Malley,Stephen Chia,Dongsheng Tu,Lois E. Shepherd,Mark N. Levine,V. Bramwell,Irene L. Andrulis,Kathleen I. Pritchard	2009	146
4	A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12) Annals of Oncology ·V. Bramwell,Kathleen I. Pritchard,Dongsheng Tu,Katia Tonkin,J.A Dorantes Romo,Ted Vandenberg,J Robert,Andrew Arnold,Sean OʼReilly,Barbara Graham,Lois E. Shepherd	2009	32
5	Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study European Journal of Cancer ·M. Nooij,Jeremy Whelan,V. Bramwell,mahdi berelyan,S. R. Cannon,Pancras C.W. Hogendoorn,J Pringle,Barbara Uscinska,Simon Weeden,A. Kirkpatrick,M. van Glabbeke,Alan Craft	2004	39
6	A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma European Journal of Cancer ·E. Gortzak,Alberto Azzarelli,J. Buesa,V. Bramwell,Frits van Coevorden,A.N. van Geel,Adnan Ezzat,Armando Santoro,J. Wolter Oosterhuis,M. van Glabbeke,A. Kirkpatrick,Jaap Verweij	2001	275
7	Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology ·Mark N. Levine,V. Bramwell,Kathleen I. Pritchard,B. Norris,Lois E. Shepherd,Hakam Abu-Zahra,B. Findlay,David Warr,David M. J. S. Bowman,James D. Myles,Andrew Arnold,Ted Vandenberg,Robert G. MacKenzie,J Robert,J. Ottaway,Margot J. Burnell,Christopher Kwesi O. Williams,فریده جزء کبیری	1998	442
8	The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. PubMed ·V. Bramwell	1997	54
9	Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma Annals of Oncology ·V. Bramwell,E. A. Eisenhauer,Martin E. Blackstein,《汉英石油技术词典》编写组,Meg Knowling,Jacques Jolivet,Claire A. Chochinov	1995	28
10	Phase II trial of 10-EDAM in advanced soft tissue sarcoma Annals of Oncology ·Margaret A. Knowling,V. Bramwell,E. Eisenhauer,《汉英石油技术词典》编写组,A. Bodurtha,Ian Quirt	1994	7
11	Timing of surgery influences survival in receptor-negative as well as receptor-positive breast cancer European Journal of Cancer ·Zahida Saad,Mark Vincent,V. Bramwell,Larry Stitt,Jennifer M. Duff,Murray J. Girotti,David C. Donald (co-author),Helen Chang,Isaiah R. Turnbull,Beatriz García	1994	14
12	Sustained Oral Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Renal Cell Carcinoma PubMed ·Noura El Haje,V. Bramwell,D Banerjee,Femida Gwadry‐Sridhar,Karl-Markus Gauss,Ranjit S. Parhar,Peeyush K. Lala	1993	12
13	Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. PubMed ·V. Bramwell,H.T. Mouridsen,Armando Santoro,G. Blackledge,R. Somers,Jaco J. Verweij,P Dombernowsky,Mathias Onsrud,Dominic Thomas,Richard Sylvester	1993	40
14	A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. Journal of Clinical Oncology ·V. Bramwell,M Burgers,R. S. Sneath,R L Souhami,Gi-Yoek Ha,P.A. Voûte,Jacques Rouëssé,D. Spooner,Alan Craft,R. Somers	1992	240
15	Chemotherapy in the multidisciplinary approach to soft tissue sarcomas Annals of Oncology ·Jaap Verweij,A.T. van Oosterom,R. Somers,Armando Santoro,Jacques Rouëssé,E. C. T.,T Türsz,Penella J. Woll,William P. Steward,J. Buesa,Pierre Kerbrat,Zhenpeng Li,V. Bramwell,D. Thomas,M. van Glabbeke,Henning T. Mouridsen	1992	18
16	Phase II trials of trimetrexate in advanced adult soft tissue sarcoma Annals of Oncology ·Elizabeth A. Eisenhauer,Ryszard Wierzbicki,Margaret A. Knowling,V. Bramwell,Ian Quirt	1991	14
17	A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. Journal of Clinical Oncology ·Mark N. Levine,Michael Gent,W M Hryniuk,V. Bramwell,Hakam Abu-Zahra,Sonja Depauw,Andrew Arnold,B. Findlay,L Levin,Jamey Skillings	1990	47
18	The place of chemotherapy in the management of soft tissue sarcoma: Experiences of the EORTC soft tissue and bone sarcoma group Clinical Oncology ·G. Blackledge,A. van Oosterom,Henning T. Mouridsen,V. Bramwell,Armando Santoro,Jaap Verweij,Jacques Rouëssé,R. Somers,T. Wagener,J. Buesa,William P. Steward,D. Spooner,Jeffrey A. Trachtenberg,David R. Thomas,Richard Sylvester	1989	4
19	Combination Chemotherapy With Doxorubicin, Dacarbazine, and Ifosfamide in Advanced Adult Soft Tissue Sarcoma JNCI Journal of the National Cancer Institute ·V. Bramwell,Ian Quirt,David Warr,Savita Verma,Vincent Young,Meg Knowling,Elizabeth A. Eisenhauer	1989	32
20	Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group European Journal of Cancer and Clinical Oncology ·Henning T. Mouridsen,Lars Bastholt,R. Somers,Armando Santoro,V. Bramwell,J.H. Mulder,A.T. van Oosterom,J. Buesa,Herbert M. Pinedo,D. Thomas,Richard Sylvester	1987	122

About V. Bramwell

V. Bramwell is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 67 papers that have together received 3.5k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (32 papers), Vascular Tumors and Angiosarcomas (23 papers), Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (14 papers), Cancer therapeutics and mechanisms (6 papers), Estrogen and related hormone effects (5 papers), HER2/EGFR in Cancer Research (4 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Internal Medicine (324 citations), Oncology (2.0k citations) and Cancer Research (784 citations). V. Bramwell has collaborated with scholars based in Canada, United Kingdom and Netherlands. Frequent co-authors include Mark N. Levine, Kathleen I. Pritchard, Armando Santoro, J. Buesa, David Warr, Lois E. Shepherd, Michael Gent, Andrew Arnold, Jacques Rouëssé and B. Findlay. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact